80 related articles for article (PubMed ID: 34170380)
21. Can LENT Prognostic score (LDH, ECOG performance score, blood neutrophil/lymphocyte ratio, tumor type) change the clinical approach in malignant pleural effusion?
Gayaf M; Anar C; Canbaz M; Doğan Bİ; Erbaycu AE; Güldaval F
Tuberk Toraks; 2021 Jun; 69(2):133-143. PubMed ID: 34256503
[TBL] [Abstract][Full Text] [Related]
22. Eosinophilic pleural effusions.
Lau MS; Pien FD
Hawaii Med J; 1990 Jun; 49(6):206-7. PubMed ID: 2397989
[TBL] [Abstract][Full Text] [Related]
23. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
[TBL] [Abstract][Full Text] [Related]
24. A new dawn for eosinophils in the tumour microenvironment.
Grisaru-Tal S; Itan M; Klion AD; Munitz A
Nat Rev Cancer; 2020 Oct; 20(10):594-607. PubMed ID: 32678342
[TBL] [Abstract][Full Text] [Related]
25. ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity.
Moral JA; Leung J; Rojas LA; Ruan J; Zhao J; Sethna Z; Ramnarain A; Gasmi B; Gururajan M; Redmond D; Askan G; Bhanot U; Elyada E; Park Y; Tuveson DA; Gönen M; Leach SD; Wolchok JD; DeMatteo RP; Merghoub T; Balachandran VP
Nature; 2020 Mar; 579(7797):130-135. PubMed ID: 32076273
[TBL] [Abstract][Full Text] [Related]
26. Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PD-1 receptor.
Tumino N; Martini S; Munari E; Scordamaglia F; Besi F; Mariotti FR; Bogina G; Mingari MC; Vacca P; Moretta L
Int J Cancer; 2019 Sep; 145(6):1660-1668. PubMed ID: 30856277
[TBL] [Abstract][Full Text] [Related]
27. Opposing roles of eosinophils in cancer.
Simon SCS; Utikal J; Umansky V
Cancer Immunol Immunother; 2019 May; 68(5):823-833. PubMed ID: 30302498
[TBL] [Abstract][Full Text] [Related]
28. Activated innate lymphoid cell populations accumulate in human tumour tissues.
Salimi M; Wang R; Yao X; Li X; Wang X; Hu Y; Chang X; Fan P; Dong T; Ogg G
BMC Cancer; 2018 Mar; 18(1):341. PubMed ID: 29587679
[TBL] [Abstract][Full Text] [Related]
29. Eosinophils: The unsung heroes in cancer?
Varricchi G; Galdiero MR; Loffredo S; Lucarini V; Marone G; Mattei F; Marone G; Schiavoni G
Oncoimmunology; 2018; 7(2):e1393134. PubMed ID: 29308325
[TBL] [Abstract][Full Text] [Related]
30. Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
Tanizaki J; Haratani K; Hayashi H; Chiba Y; Nakamura Y; Yonesaka K; Kudo K; Kaneda H; Hasegawa Y; Tanaka K; Takeda M; Ito A; Nakagawa K
J Thorac Oncol; 2018 Jan; 13(1):97-105. PubMed ID: 29170120
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients.
Lee YS; Nam HS; Lim JH; Kim JS; Moon Y; Cho JH; Ryu JS; Kwak SM; Lee HL
BMC Cancer; 2017 Aug; 17(1):557. PubMed ID: 28830378
[TBL] [Abstract][Full Text] [Related]
32. Emerging Roles for Eosinophils in the Tumor Microenvironment.
Reichman H; Karo-Atar D; Munitz A
Trends Cancer; 2016 Nov; 2(11):664-675. PubMed ID: 28741505
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
34. Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy.
Moreira A; Leisgang W; Schuler G; Heinzerling L
Immunotherapy; 2017 Jan; 9(2):115-121. PubMed ID: 28128709
[TBL] [Abstract][Full Text] [Related]
35. Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.
Weide B; Martens A; Hassel JC; Berking C; Postow MA; Bisschop K; Simeone E; Mangana J; Schilling B; Di Giacomo AM; Brenner N; Kähler K; Heinzerling L; Gutzmer R; Bender A; Gebhardt C; Romano E; Meier F; Martus P; Maio M; Blank C; Schadendorf D; Dummer R; Ascierto PA; Hospers G; Garbe C; Wolchok JD
Clin Cancer Res; 2016 Nov; 22(22):5487-5496. PubMed ID: 27185375
[TBL] [Abstract][Full Text] [Related]
36. Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab.
Gebhardt C; Sevko A; Jiang H; Lichtenberger R; Reith M; Tarnanidis K; Holland-Letz T; Umansky L; Beckhove P; Sucker A; Schadendorf D; Utikal J; Umansky V
Clin Cancer Res; 2015 Dec; 21(24):5453-9. PubMed ID: 26289067
[TBL] [Abstract][Full Text] [Related]
37. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells.
Carretero R; Sektioglu IM; Garbi N; Salgado OC; Beckhove P; Hämmerling GJ
Nat Immunol; 2015 Jun; 16(6):609-17. PubMed ID: 25915731
[TBL] [Abstract][Full Text] [Related]
38. Important prognostic factors for survival in patients with malignant pleural effusion.
Zamboni MM; da Silva CT; Baretta R; Cunha ET; Cardoso GP
BMC Pulm Med; 2015 Mar; 15():29. PubMed ID: 25887349
[TBL] [Abstract][Full Text] [Related]
39. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score.
Clive AO; Kahan BC; Hooper CE; Bhatnagar R; Morley AJ; Zahan-Evans N; Bintcliffe OJ; Boshuizen RC; Fysh ET; Tobin CL; Medford AR; Harvey JE; van den Heuvel MM; Lee YC; Maskell NA
Thorax; 2014 Dec; 69(12):1098-104. PubMed ID: 25100651
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
